Selank

What it is

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is structurally based on tuftsin (a tetrapeptide fragment of immunoglobulin G) with a tripeptide extension that confers metabolic stability and CNS activity. Selank is approved as a pharmaceutical in Russia (Селанк) for generalized anxiety disorder and asthenic conditions but has not received approval in the United States or Western Europe.

The peptide was developed beginning in the 1980s as part of Russian research into peptide-based pharmaceuticals for neuropsychiatric indications. Selank and its sister peptide Semax represent a class of “regulatory peptides” — short, stable peptides intended to modulate native CNS systems through targeted receptor interactions. In the US, Selank is available through licensed compounding pharmacies for clinical use.

Mechanism of action

Selank’s mechanism integrates effects on multiple neurotransmitter systems and neurotrophic pathways:

• GABAergic modulation: Selank enhances GABAergic neurotransmission, contributing to anxiolytic effects. Unlike benzodiazepines, this modulation occurs without the receptor desensitization patterns that lead to tolerance and dependence.
• Serotonergic effects: influences serotonin metabolism in ways that contribute to mood and anxiety regulation.
• BDNF and neurotrophic effects: upregulates brain-derived neurotrophic factor expression in hippocampal regions, potentially supporting cognitive function and stress resilience.
• Immune system effects: Selank retains some of tuftsin’s immunomodulatory activity, increasing certain cytokine and immunoglobulin levels — a less clinically relevant aspect for neuropsychiatric use but consistent with its tuftsin-derived origin.
• Stable, non-sedating profile: the anxiolytic effects occur without the sedation, motor impairment, or cognitive blunting characteristic of benzodiazepine and other GABA-positive modulators.

Intranasal administration provides direct nose-to-brain peptide delivery, bypassing first-pass metabolism and providing rapid CNS effects.

Research findings

The Russian clinical literature on Selank is substantial:

Generalized anxiety disorder: randomized clinical trials in Russia have demonstrated efficacy comparable to medazepam (a benzodiazepine) without sedation, dependence, or withdrawal symptoms. The Selank approval in Russia rests on this evidence base.

Asthenic conditions: Russian indication encompasses conditions of nervous exhaustion, post-illness fatigue, and adjustment disorders.

Cognitive effects: some studies suggest improvements in attention and learning under stress conditions, attributed to BDNF-related mechanisms.

Western RCT replication is limited. The published Russian literature is mostly in Russian-language journals; Western clinical use is informed by these studies, by mechanistic understanding, and by accumulating practitioner experience.

How we use it at The Tide

We prescribe Selank selectively for patients with situational anxiety, performance anxiety, or mild generalized anxiety symptoms who want a non-benzodiazepine option for short-term symptom management. Typical scenarios:

• Performance anxiety in specific contexts (presentations, social events, travel)
• Adjustment-period anxiety during life transitions
• Mild generalized anxiety symptoms not warranting psychiatric medication
• As an adjunct in patients reducing benzodiazepine use under appropriate medical supervision

Important boundaries: Selank is not a substitute for psychiatric care in patients with significant anxiety disorders. We refer patients with moderate-to-severe anxiety, panic disorder, OCD, or PTSD to appropriate mental health care. Selank may be a useful adjunct in some of these scenarios but is not first-line treatment.

Standard dosing: 0.15% intranasal spray, 1–2 sprays per nostril, 1–3 times daily. Cycles are typically 2–4 weeks, with breaks between cycles. Some patients use Selank as-needed for specific anxiety-provoking situations.

Side effects and contraindications

Selank is well-tolerated in published trials and clinical use:

• Mild nasal irritation with intranasal use
• Occasional mild headache
• Rare metallic taste in mouth shortly after dosing

Notably, the published evidence base shows no signal of dependence, withdrawal, or tolerance — distinguishing Selank from benzodiazepines and other anxiolytics. Long-term human safety data outside Russian clinical practice is limited.

Avoided in: pregnancy and breastfeeding, severe psychiatric conditions where psychiatric care is indicated, patients with known peptide allergies.

What we don’t yet know

Western RCT replication of Russian efficacy claims would strengthen the evidence base substantially. Long-term safety with chronic or repeated cyclical use over many years is not well characterized. Optimal dosing patterns for various indications are largely empirical. Comparative effectiveness vs. conventional anxiolytics, SSRIs, and behavioral interventions is not well documented in head-to-head studies. Selank represents a peptide where the international evidence base is meaningfully larger than the US-published literature, used selectively in appropriate patients with realistic expectations about effect size and the central role of behavioral and lifestyle approaches to anxiety.